Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles

Andres F. Mejia; Timothy D. Culp; Nancy M. Cladel; Karla K. Balogh; Lynn R. Budgeon; Christopher B. Buck; Neil D. Christensen

doi:10.1128/JVI.01583-06

Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles

Andres F. Mejia, Timothy D. Culp, Nancy M. Cladel, Karla K. Balogh, Lynn R. Budgeon, Christopher B. Buck, Neil D. Christensen

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.

Original language	English (US)
Pages (from-to)	12393-12397
Number of pages	5
Journal	Journal of virology
Volume	80
Issue number	24
DOIs	https://doi.org/10.1128/JVI.01583-06
State	Published - Dec 2006

All Science Journal Classification (ASJC) codes

Microbiology
Immunology
Insect Science
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/JVI.01583-06

Cite this

@article{7154cc98fede4b828c3165eb59c2c173,

title = "Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles",

abstract = "A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.",

author = "Mejia, {Andres F.} and Culp, {Timothy D.} and Cladel, {Nancy M.} and Balogh, {Karla K.} and Budgeon, {Lynn R.} and Buck, {Christopher B.} and Christensen, {Neil D.}",

year = "2006",

month = dec,

doi = "10.1128/JVI.01583-06",

language = "English (US)",

volume = "80",

pages = "12393--12397",

journal = "Journal of virology",

issn = "0022-538X",

publisher = "American Society for Microbiology",

number = "24",

}

TY - JOUR

T1 - Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles

AU - Mejia, Andres F.

AU - Culp, Timothy D.

AU - Cladel, Nancy M.

AU - Balogh, Karla K.

AU - Budgeon, Lynn R.

AU - Buck, Christopher B.

AU - Christensen, Neil D.

PY - 2006/12

Y1 - 2006/12

N2 - A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.

AB - A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.

UR - http://www.scopus.com/inward/record.url?scp=33845449841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845449841&partnerID=8YFLogxK

U2 - 10.1128/JVI.01583-06

DO - 10.1128/JVI.01583-06

M3 - Article

C2 - 17005666

AN - SCOPUS:33845449841

SN - 0022-538X

VL - 80

SP - 12393

EP - 12397

JO - Journal of virology

JF - Journal of virology

IS - 24

ER -

Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this